Oruka Therapeutics Business Summary

Oruka Therapeutics, Inc. (ORKA) is a clinical-stage biotechnology company that generates value through the development of a proprietary portfolio of novel biologics for chronic skin diseases, including plaque psoriasis, psoriatic arthritis, and hidradenitis suppurativa. The company does not currently generate product revenue, instead relying on capital markets and private placements—including a $275 million financing in late 2024—to fund its single business segment focused on immunology and dermatology. Oruka’s lead programs, ORKA-001 (targeting IL-23p19) and ORKA-002 (targeting IL-17A/F), utilize advanced antibody engineering to achieve significantly extended half-lives, aiming for once- or twice-yearly dosing. The company competes directly with established industry leaders such as AbbVie (Skyrizi), Eli Lilly (Taltz), UCB (Bimzelx), and Johnson & Johnson (Tremfya). Oruka differentiates itself by positioning its candidates as potentially best-in-class alternatives that offer superior dosing convenience and deeper, more durable clinical responses compared to existing standard-of-care therapies. Oruka was founded by Fairmount Funds and Paragon Therapeutics and is led by a management team with extensive pedigree in biopharmaceutical development and commercialization. Chief Executive Officer Lawrence Klein, PhD, previously served as the Chief Operating Officer of CRISPR Therapeutics, while Chief Medical Officer Joana Goncalves, MBChB, joined from Dermavant Sciences where she oversaw the development of Vtama. Other key executives include Chief Operating Officer Laura Sandler and General Counsel Paul Quinlan, formerly of CymaBay Therapeutics. The company’s strategic direction is further guided by a high-profile Board of Directors chaired by Samarth Kulkarni, PhD (CEO of CRISPR Therapeutics), and including Peter Harwin of Fairmount Funds and commercial veteran Chris Martin, who joined in late 2025. Oruka is backed by a robust syndicate of institutional investors, including Deep Track Capital, RTW Investments, and Venrock Healthcare Capital Partners, providing a cash runway that extends through 2027.